Bergua Burgués, Juan Miguel | Hematología y Hemoterapia |

Resultados: 294
Tipo Título / Nombre Autor(es) Año
Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study Barragán E, Gil JV, Ayala R, Chillón C..., Bergua J 2026
Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial Vitolo U, Burgues JMB, Duell J, Kwiatek M, Belada D, Jurczak W, Maerevoet M, Sibon D, Greil R, Kumode T, López-Jimenez J, Meert C, Cia JS, Thieblemont C, Alcaide SO, Kim WS, Cordoba R, Wielgos-Bonvallet M, Jiang T, Wang Y, McGoldrick S, Guo E, Morschhauser F, Woei-A-Jin FJSH 2026
Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study Gil JV, Sargas C, Ayala R, Gutierrez NC..., Bergua Burgues JM 2026
Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group Colmenares R, Barragán E, Rodríguez-Veiga R, Torres-Miñana L..., Bergua J 2026
Genetics and MRD for therapy allocation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia Ribera JM, Torrent A, Morgades M..., Bergua Burgues JM 2026
Real-World Outcomes of FLAG-Ida Regimen in 1079 Adult Patients With First Relapsed/Refractory AML: A PETHEMA Study Aspas Requena G, Rodríguez-Veiga R, Gil C, Botella C, Aguiar E..., Bergua Burgues JM 2026
Desaparición espontánea de un inhibidor bajo tratamiento con Emicizumab en un paciente con Hemofilia A leve Domínguez Mora AR, Bermejo Vega N, Calzadilla Román KS, Casado Cabanillas V, Macías Maeso J, Román Molano LG, Higuero Saavedra V, Moriano Palacios BJ, Cáceres Hernández S, Casas Avilés I, Bañas Llanos MH, Arcos Carmona MJ, Ibáñez Espacio F, Ugalde Fernández N, Cabrera Silva MC, Carnicero González F, Bergua Burgués JM 2026
Debut de mastocitosis sistémica en relación a la colocación de DIU hormonal Domínguez Mora AR, Calzadilla Román KS, Casado Cabanillas V, Macías Maesp J, Rodríguez Alamo YC, Román Molano LG, Higuero Saavedra V, Moriano Palacios BJ, Cáceres Hernández S, Casas Avilés I, Bañas LLanos MH, Arcos Carmona MJ, Ibáñez Espacio F, Ugalde Fernández N, Cabrera Silva MC, Carnicero González F, Bergua Burgués JM 2026
Intensive Chemotherapy With or Without Midostaurin in Adults ? 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study Aspas Requena G, Montesinos P, Bérard E, Bertoli S..., Bergua Burgues JM 2026
CEBPA-bZIP Mutations in AML Patients Treated With Non-Intensive Therapy: A Study by the Spanish PETHEMA Registry Prados de la Torre E, Serrano J, Barragán E, Ayala R..., Bergua Burgues JM 2026